3 unknown, 2 terminated, 1 recruiting. 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Unknown 2 |
| Phase 2 | 1 | Terminated 1 |
Follow Insulin-Like Growth Factor I Deficiency: new trials by email Literature Review of Insulin-Like Growth Factor I Deficiency trials Research Report on Insulin-Like Growth Factor I Deficiency
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of a HIIT Program on Quality of Life, Executive Functions, and IGF-1 Response in Sedentary Young University Women HIIT, HIIT+PA, CON - Insulin Growth Factor I Deficiency, IGF1 Deficiency | Not applicable | Unknown | University of Seville | 75 | 2022-10-15 | 2022-12-08 |
| AR, IGF-IR, IR and Peripheral Artery Disease arterial reconstructive open surgery - Androgen Receptor Abnormal, Insulin-Like Growth Factor I Deficiency | Unknown | University of Catanzaro | 30 | 2018-08-01 | 2021-01-14 | |
| Effect of Maternal BMI and Type of Infants Feeding on IGF-1 in Infant level of IGF-1 in infants - IGF1 Deficiency | Not applicable | Unknown | Assiut University | 40 | 2017-12-01 | 2017-09-07 |
| IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population IGF-1 Deficiency | Terminated | Ipsen | 304 | 2012-07-01 | 2019-01-11 | |
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). Increlex® - IGF1 Deficiency | Recruiting | Esteve Pharmaceuticals, S.A. | 500 | 2008-12-09 | 2026-02-06 | |
| rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) - Insulin-like Growth Factor-1 Deficiency | Phase 2 | Terminated | Ipsen | 106 | 2007-12-01 | 2023-03-30 |
Bulbo-Spinal Atrophy, X-Linked (1) · Insulin Receptor, Defect in (1) · Peripheral Arterial Disease (1) · Puberty, Delayed (1)
Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Gonadal Disorders (1) · Heredodegenerative Disorders, Nervous System (1) · Motor Neuron Disease (1) · Muscular Atrophy, Spinal (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1)
mecasermin (2) · Human Growth Hormone (1) · Injections (1)
Ipsen (2) · Assiut University (1) · Esteve Pharmaceuticals, S.A. (1) · University of Catanzaro (1) · University of Seville (1)
Spain (3) · Italy (2) · United States (2) · Austria (1) · France (1) · French Guiana (1) · Germany (1) · Martinique (1) · Poland (1) · Sweden (1) · United Kingdom (1)
Manuel Jesus Jimenez Roldan (1) · Marcello Maggiolini, M.D. (1) · Raffaele Serra, M.D., Ph.D. (1)
PMID 11726732, PMID 33401605, PMID 33434161, PMID 35250870, PMID 37579214, PMID 3956421, PMID 40626687
2019 (1)